- About Us
- Nano-Social Network
- Nano Consulting
- My Account
MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell
loading systems, announces it will host a Lunch Briefing on January 22nd at the Phacilitate Cell and Gene Therapy Forum in Baltimore, Maryland with featured speaker Dan Gazit, PhD, DMD, Head of the Skeletal Biotech Laboratory, Director of the Hebrew University Center for Converging Sciences & Technologies, and Director of Stem Cell Therapeutics Research Lab, Department of Surgery and International Stem cell Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Dr. Gazit's presentation entitled "Genetically Engineered Stem Cells as a Platform for Skeletal Tissue Engineering" will discuss how genetically engineered mesenchymal stem cells are able to regenerate bone, cartilage, tendon, ligaments and intervertebral disk and how non-viral gene delivery works efficiently for mesenchymal stem cells.
Dr. Gazit is Professor and Head of the Skeletal Biotech Laboratory, Director of the Hebrew University Center for Converging Sciences & Technologies, Hebrew University, Jerusalem, Israel, and Director of Stem Cell Therapeutics Research Lab, Department of Surgery and International Stem cell Institute, Cedars-Sinai Medical Center, Los Angeles, CA. He received his academic training at the Hebrew University (DMD in Dental Medicine and PhD in bone biology) and joined the faculty of Dental Medicine in 1981 as a specialist in oral pathology. After a postdoctoral training in the University of California, San Francisco, he returned to the Hebrew University to become the head of the Skeletal Biotech Laboratory (1992-present), and Full Professor of Skeletal Biotechnology (2002-present). Dr. Gazit is world renowned for his work in musculoskeletal tissue engineering and orthopedic gene therapy. His scientific interests include adult stem cell biology, skeletal tissue engineering, gene therapy, non-invasive imaging, and nanotechnology. In these areas he has published
nearly 100 peer-reviewed papers and book chapters. He is especially interested in projects that bring together several scientific disciplines in order to advance stem cell-based therapeutic approaches in regenerative medicine.
For information on attending the lunch briefing, please contact MaxCyte.
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies.
MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.
For more information, visit http://www.maxcyte.com.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
For more information, please click here
22 Firstfield Road, Suite 250
Gaithersburg, MD 20878
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016
Leti Presents Advances in Propagation Modeling and Antenna Design for mmWave Spectrum: Paper Is One of 15 that Leti Presented at European Conference on Antennas and Propagation March 19-24 March 23rd, 2017
Next-gen steel under the microscope March 18th, 2017
UC researchers use gold coating to control luminescence of nanowires: University of Cincinnati physicists manipulate nanowire semiconductors in pursuit of making electronics smaller, faster and cheaper March 17th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017